Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: A systematic review of current evidence and future prospects (Review)
- Authors:
- Cheng Ma
- Xinlin Yu
- Xialin Zhang
- Lihong Su
- Ou Jiang
- Ran Cui
-
Affiliations: Department of Oncology, The First People's Hospital of Neijiang, Neijiang, Sichuan 641000, P.R. China, Department of Oncology, The Affiliated Hospital of Chengdu University, Chengdu, Sichuan 610000, P.R. China, Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China - Published online on: May 14, 2025 https://doi.org/10.3892/ol.2025.15088
- Article Number: 342
-
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
|
Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L and Di Tommaso L: Hepatocellular carcinoma: A clinical and pathological overview. Pathologica. 113:203–217. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Montal R, Sia D and Finn RS: Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 15:599–616. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sangro B, Sarobe P, Hervas-Stubbs S and Melero I: Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 18:525–543. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 389:2492–2502. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, et al: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M: Combination cancer immunotherapy in hepatocellular carcinoma. Liver Cancer. 7:20–27. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, et al: Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 24:1845–1851. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sharabi AB, Lim M, DeWeese TL and Drake CG: Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16:e498–e509. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dendy MS, Ludwig JM, Stein SM and Kim HS: Locoregional therapy, immunotherapy and the combination in hepatocellular carcinoma: Future directions. Liver Cancer. 8:326–340. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu S, Chao Y, Hu Y, Zhang Y, Hong W, Chen Y, Chen R, Zeng Z and Du S: Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: A propensity-matched real-world study. Chin Med J (Engl). 137:1332–1342. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL and Drake CG: Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 3:345–355. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S and Formenti SC: Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 18:313–322. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Zhang H, Xin Zhang and Liu Y: Abscopal effect: From a rare phenomenon to a new frontier in cancer therapy. Biomark Res. 12:982024. View Article : Google Scholar : PubMed/NCBI | |
|
Formenti SC and Demaria S: Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst. 105:256–265. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Correction. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 8:e000337corr12020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JY, Kim DH, Kim JH, Lee D, Jeon HB, Kwon SJ, Kim SM, Yoo YJ, Lee EH, Choi SJ, et al: Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques. Cell Death Differ. 19:680–691. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Demaria S, Coleman CN and Formenti SC: Radiotherapy: Changing the game in immunotherapy. Trends Cancer. 2:286–294. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C and Depil S: Cold Tumors: A therapeutic challenge for immunotherapy. Front Immunol. 10:1682019. View Article : Google Scholar : PubMed/NCBI | |
|
Friedman D, Baird JR, Young KH, Cottam B, Crittenden MR, Friedman S, Gough MJ and Newell P: Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma. Hepatol Res. 47:702–714. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rimassa L, Finn RS and Sangro B: Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 79:506–515. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Tojjari A, Yu J and Saeed A: Immunotherapy and radiation therapy combinatorial approaches in hepatocellular carcinoma. Cancers (Basel). 16:10582024. View Article : Google Scholar : PubMed/NCBI | |
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dawood ZS, Brown ZJ, Alaimo L, Lima HA, Shaikh C, Katayama ES, Munir MM, Moazzam Z, Endo Y, Woldesenbet S and Pawlik TM: Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors-a systematic review and meta-analysis. HPB (Oxford). 26:618–629. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YH, Tai D, Yip C, Choo SP and Chew V: Combinational immunotherapy for hepatocellular carcinoma: Radiotherapy, immune checkpoint blockade and beyond. Front Immunol. 11:5687592020. View Article : Google Scholar : PubMed/NCBI | |
|
Bicak M, Cimen Bozkus C and Bhardwaj N: Checkpoint therapy in cancer treatment: Progress, challenges, and future directions. J Clin Invest. 134:e1848462024. View Article : Google Scholar : PubMed/NCBI | |
|
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 124:687–695. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, et al: Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 25:2116–2126. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Zhou J, Wu M, Hu C, Yang J, Li D, Wu P, Chen Y, Chen P, Lin S, et al: Low-dose total body irradiation can enhance systemic immune related response induced by hypo-fractionated radiation. Front Immunol. 10:3172019. View Article : Google Scholar : PubMed/NCBI | |
|
Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al: Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 24:589–602. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Li K, Wang K, Yu H, Wang X, Shi M, Liang Z, Yang Z, Hu Y, Li Y, et al: Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells. Nat Commun. 14:77092023. View Article : Google Scholar : PubMed/NCBI | |
|
Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, Abei M, Kawaguchi A, Hayashi Y, Ookawa A, et al: Proton beam therapy for hepatocellular carcinoma: A comparison of three treatment protocols. Int J Radiat Oncol Biol Phys. 81:1039–1045. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ and Feng M: Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 34:452–459. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, et al: Phase 1 Randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced/unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 115:202–213. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Ji X, Sun J, Zhang A, Jia J, Zhang T, Li W and Duan X: Stereotactic body radiotherapy combined with lenvatinib with or without PD-1 inhibitors as initial treatment for unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 120:1363–1376. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Li JX, Su TS, Gong WF, Zhong JH, Yan LY, Zhang J, Li LQ, He ML, Zhang RJ, Du YQ, et al: Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: A single-arm trial. Hepatol Int. 16:1179–1187. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang CL, Chan ACY, Chiu KWH and Kong FS: Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: A potential synergistic treatment strategy. Front Oncol. 9:11572019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Q, Xie J, Mei W and Zeng C: Methylated circulating tumor DNA in hepatocellular carcinoma: A comprehensive analysis of biomarker potential and clinical implications. Cancer Treat Rev. 128:1027632024. View Article : Google Scholar : PubMed/NCBI | |
|
Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, et al: Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 16:1155–1161. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Howell J, Atkinson SR, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Buttner R, et al: Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer. 116:56–66. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Angeli-Pahim I, Chambers A, Duarte S, Soma D, Beduschi T, Sahin I, Hughes S and Zarrinpar A: Methylated ctDNA quantification: Noninvasive approach to monitoring hepatocellular carcinoma burden. J Am Coll Surg. 238:770–778. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fridman WH, Zitvogel L, Sautes-Fridman C and Kroemer G: The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 14:717–734. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, et al: A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging biomarker, retrospective multicohort study. Lancet Oncol. 19:1180–1191. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Han X, Guo Y, Ye H, Chen Z, Hu Q, Wei X, Liu Z and Liang C: Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response. Breast Cancer Res. 26:182024. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J and Jung Y: Radiation-induced liver disease: Current understanding and future perspectives. Exp Mol Med. 49:e3592017. View Article : Google Scholar : PubMed/NCBI | |
|
Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD and Fajardo LF: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 31:1237–1248. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ and Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21:109–122. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Rammohan N, Randall JW and Yadav P: History of technological advancements towards MR-Linac: The future of image-guided radiotherapy. J Clin Med. 11:47302022. View Article : Google Scholar : PubMed/NCBI | |
|
Khaledi N, Khan R and Gräfe JL: Historical progress of stereotactic radiation surgery. J Med Phys. 48:312–327. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Khoo VS, Dearnaley DP, Finnigan DJ, Padhani A, Tanner SF and Leach MO: Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Radiother Oncol. 42:1–15. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, Brown MB, DuRoss DJ, Andrews JC, Ensminger WD, et al: The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 23:781–788. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Timmerman RD, Kavanagh BD, Cho LC, Papiez L and Xing L: Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 25:947–952. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Ke Q, Huang Q, Shao L, Chen J and Wu J: Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: A systematic review and meta-analysis. Int J Hyperthermia. 37:1313–1321. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu DH, Liu L and Chen LH: Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 10:2184–2189. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Blomgren H, Lax I, Naslund I and Svanstrom R: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 34:861–870. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Hall JT, Moon AM, Young M, Tan X, Darawsheh R, Danquah F, Tepper JE and Yanagihara TK: Biochemical safety of SBRT to multiple intrahepatic lesions for hepatocellular carcinoma. J Hepatocell Carcinoma. 11:443–454. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Hardy-Abeloos C, Lazarev S, Ru M, Kim E, Fischman A, Moshier E, Rosenzweig K and Buckstein M: Safety and efficacy of liver stereotactic body radiation therapy for hepatocellular carcinoma after segmental transarterial Radioembolization. Int J Radiat Oncol Biol Phys. 105:968–976. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Park SH, Kim JC and Kang MK: Technical advances in external radiotherapy for hepatocellular carcinoma. World J Gastroenterol. 22:7311–7321. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Koay EJ, Owen D and Das P: Radiation-induced liver disease and modern radiotherapy. Semin Radiat Oncol. 28:321–331. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J and Johnstone PA: Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 12:218–225. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, Ringash J and Dawson LA: Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol. 111:412–417. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, Hallemeier CL, Koay EJ, Lasley F, Meyer J, et al: External beam radiation therapy for primary liver cancers: An ASTRO clinical practice guideline. Pract Radiat Oncol. 12:28–51. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Mayo CS, Moran JM, Bosch W, Xiao Y, McNutt T, Popple R, Michalski J, Feng M, Marks LB, Fuller CD, et al: American association of physicists in medicine task Group 263: Standardizing nomenclatures in radiation oncology. Int J Radiat Oncol Biol Phys. 100:1057–1066. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Schaub SK, Hartvigson PE, Lock MI, Hoyer M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS and Apisarnthanarax S: Stereotactic body radiation therapy for hepatocellular carcinoma: Current trends and controversies. Technol Cancer Res Treat. 17:15330338187902172018. View Article : Google Scholar : PubMed/NCBI | |
|
Rim CH and Seong J: Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J. 34:160–167. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Crane CH and Koay EJ: Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance. Cancer. 122:1974–1986. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Deng GL, Zeng S and Shen H: Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol. 7:787–798. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang A, Yang XR, Chung WY, Dennison AR and Zhou J: Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 5:1462020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SU and Kim TH: Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma. Clin Mol Hepatol. 29:958–968. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, Rudqvist NP, Formenti SC and Demaria S: Barriers to radiation-induced in situ tumor vaccination. Front Immunol. 8:2292017. View Article : Google Scholar : PubMed/NCBI | |
|
Lu Z, Polan DF, Wei L, Aryal MP, Fitzpatrick K, Wang C, Cuneo KC, Evans JR, Roseland ME, Gemmete JJ, et al: PET/CT-based absorbed dose maps in (90)Y selective internal radiation therapy correlate with spatial changes in liver function derived from dynamic MRI. J Nucl Med. 65:1224–1230. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, et al: Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): A single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 8:169–178. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, et al: Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A Randomized, double-blind, phase III trial. J Clin Oncol. 38:193–202. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M, Matilla A, Santoro A, Melero I, Gracian AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, et al: CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 75:600–609. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wherry EJ and Kurachi M: Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, et al: Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol. 6:e2045642020. View Article : Google Scholar : PubMed/NCBI | |
|
Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, et al: Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 73:1460–1469. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ringelhan M, Pfister D, O'Connor T, Pikarsky E and Heikenwalder M: The immunology of hepatocellular carcinoma. Nat Immunol. 19:222–232. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, et al: Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 153:812–826. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng AL, Hsu C, Chan SL, Choo SP and Kudo M: Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 72:307–319. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ning C, Zhang X, Wang Y, Yang X, Yang X, Chao J, Xun Z, Xue J, Wang Y, Sun H, et al: Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 118:1461–1471. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Song Y, Fu Y, Xie Q, Zhu B, Wang J and Zhang B: Anti-angiogenic agents in combination with immune checkpoint inhibitors: A promising strategy for cancer treatment. Front Immunol. 11:19562020. View Article : Google Scholar : PubMed/NCBI | |
|
Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H and Zamani M: Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 22:22022. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al: Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, Ikeda M, Tsuchiya K, Aoki KI, Jia J and Lencioni R: IMbrave150: Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in patients with barcelona clinic liver cancer stage B unresectable hepatocellular carcinoma: An exploratory analysis of the phase III study. Liver Cancer. 12:238–250. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Fukumura D, Kloepper J, Amoozgar Z, Duda DG and Jain RK: Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol. 15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ali S, Arshad M, Summer M, Zulfiqar M, Noor S, Nazakat L and Javed MA: Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer. J Oncol Pharm Pract. Mar 28–2025.(Epub ahead of print). View Article : Google Scholar | |
|
Osaki M and Sakaguchi S: Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity. Immunity. 58:889–908.e13. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, et al: Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 35:448–457. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Wei SC, Duffy CR and Allison JP: Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8:1069–1086. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Saygin I, Cakir E, Kazaz SN, Guvercin AR, Eyupoglu I and Ustaoglu MM: Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry. Turk J Med Sci. 54:735–743. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Liu X, Chen D and Yu J: Radiotherapy combined with immunotherapy: The dawn of cancer treatment. Signal Transduct Target Ther. 7:2582022. View Article : Google Scholar : PubMed/NCBI | |
|
Chang Y, Chang M, Bao X and Dong C: Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment. Bioact Mater. 42:379–403. 2024.PubMed/NCBI | |
|
Garg AD, Nowis D, Golab J, Vandenabeele P, Krysko DV and Agostinis P: Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim Biophys Acta. 1805:53–71. 2010.PubMed/NCBI | |
|
Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P and Vandenabeele P: Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 12:860–875. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al: Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 6:5882015. View Article : Google Scholar : PubMed/NCBI | |
|
Galluzzi L, Buque A, Kepp O, Zitvogel L and Kroemer G: Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 17:97–111. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 13:1050–1059. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al: Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 15:1170–1178. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN and Vandenabeele P: Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 32:157–164. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Palm NW and Medzhitov R: Pattern recognition receptors and control of adaptive immunity. Immunol Rev. 227:221–233. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rock KL and Kono H: The inflammatory response to cell death. Annu Rev Pathol. 3:99–126. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zitvogel L, Kepp O and Kroemer G: Decoding cell death signals in inflammation and immunity. Cell. 140:798–804. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Oura K, Morishita A, Tani J and Masaki T: Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review. Int J Mol Sci. 22:58012021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen R, Du J, Zhu H and Ling Q: The role of cGAS-STING signalling in liver diseases. JHEP Rep. 3:1003242021. View Article : Google Scholar : PubMed/NCBI | |
|
Ren B, Luo S, Xu F, Zou G, Xu G, He J, Huang Y, Zhu H and Li Y: The expression of DAMP proteins HSP70 and cancer-testis antigen SPAG9 in peripheral blood of patients with HCC and lung cancer. Cell Stress Chaperones. 22:237–244. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Amiri M, Molavi O, Sabetkam S, Jafari S and Montazersaheb S: Stimulators of immunogenic cell death for cancer therapy: Focusing on natural compounds. Cancer Cell Int. 23:2002023. View Article : Google Scholar : PubMed/NCBI | |
|
Singh V, Kaur R, Kumari P, Pasricha C and Singh R: ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders. Clin Chim Acta. 548:1174872023. View Article : Google Scholar : PubMed/NCBI | |
|
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar : PubMed/NCBI | |
|
Pandey P, Khan F, Qari HA, Upadhyay TK, Alkhateeb AF and Oves M: Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals (Basel). 15:3352022. View Article : Google Scholar : PubMed/NCBI | |
|
Yu S, Jiang S, Zhou Y, Zhu Z and Yang X: Impact of radiation on exosomes in regulating tumor immune microenvironment. Adv Radiat Oncol. 9:1015492024. View Article : Google Scholar : PubMed/NCBI | |
|
Pedros C, Canonigo-Balancio AJ, Kong KF and Altman A: Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity. JCI Insight. 2:e956922017. View Article : Google Scholar : PubMed/NCBI | |
|
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 520:373–377. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Binder DC, Fu YX and Weichselbaum RR: Radiotherapy and immune checkpoint blockade: Potential interactions and future directions. Trends Mol Med. 21:463–465. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Dong Y, Kong L, Shi F, Zhu H and Yu J: Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 11:1042018. View Article : Google Scholar : PubMed/NCBI | |
|
Bae SH, Chun SJ, Chung JH, Kim E, Kang JK, Jang WI, Moon JE, Roquette I, Mirabel X, Kimura T, et al: Stereotactic body radiation therapy for hepatocellular carcinoma: meta-analysis and international stereotactic radiosurgery society practice guidelines. Int J Radiat Oncol Biol Phys. 118:337–351. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Schaue D and McBride WH: Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 12:527–540. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang YJ, Wang K, Zheng YT, Feng S, Yu HM, Li XW, Cheng X, Cheng YQ, Feng JK, Zhou LP, et al: Effects of stereotactic body radiation therapy plus PD-1 inhibitors for patients with transarterial chemoembolization refractory. Front Oncol. 12:8396052022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhai J, Gu X, Liu Y, Hu Y, Jiang Y and Zhang Z: Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Front Pharmacol. 14:11529342023. View Article : Google Scholar : PubMed/NCBI | |
|
Kroemer G, Galassi C, Zitvogel L and Galluzzi L: Immunogenic cell stress and death. Nat Immunol. 23:487–500. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Manda K, Glasow A, Paape D and Hildebrandt G: Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells. Front Oncol. 2:1022012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim KJ, Lee HW and Seong J: Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. J Gastroenterol Hepatol. 36:1357–1365. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, et al: Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Zhao L, Fu K, Lin Q, Wen X, Jacobson O, Sun L, Wu H, Zhang X, Guo Z, et al: Integrin α(v)β(3)-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy. Theranostics. 9:7948–7960. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shao Y, Han S, Hou Z, Yang C and Zhao Y: Tumor-associated macrophages within the immunological milieu: An emerging focal point for therapeutic intervention. Heliyon. 10:e368392024. View Article : Google Scholar : PubMed/NCBI | |
|
Tai WM, Yong WP, Lim C, Low LS, Tham CK, Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, et al: A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol. 27:2210–2215. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim BH, Park HC, Kim TH, Koh YH, Hong JY, Cho Y, Sinn DH, Park B and Park JW: Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study. JHEP Rep. 6:1009912023. View Article : Google Scholar : PubMed/NCBI | |
|
Buckstein M, Kim E, Ozbek U, Tabrizian P, Gunasekaran G, Facciuto M, Rosenzweig K, Llovet JM and Schwartz M: Combination transarterial chemoembolization and stereotactic body radiation therapy for unresectable single large hepatocellular carcinoma: Results from a prospective phase 2 trial. Int J Radiat Oncol Biol Phys. 114:221–230. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang CL, Chiu KW, Lee FA, Kong FS and Chan AC: Combined stereotactic body radiotherapy and immunotherapy versus transarterial chemoembolization in locally advanced hepatocellular carcinoma: A propensity score matching analysis. Front Oncol. 11:7988322021. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang CL, Lee FAS, Chan KSK, Lee VWY, Chiu KWH, Ho RLM, Fong JKS, Wong NSM, Yip WWL, Yeung CSY, et al: Survival outcome analysis of stereotactic body radiotherapy and immunotherapy (SBRT-IO) versus SBRT-alone in unresectable hepatocellular carcinoma. Liver Cancer. 13:265–276. 2023.PubMed/NCBI | |
|
Ning C, Jia J, Zhang X, Sun J, Wang Y, Xue J, Zhang L, Hou X, Yang X, Sang X, et al: Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors. Hepatobiliary Surg Nutr. 12:882–897. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, et al: Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 21:3727–3739. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC and Demaria S: DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 8:156182017. View Article : Google Scholar : PubMed/NCBI | |
|
Robbins JR, Schmid RK, Hammad AY, Gamblin TC and Erickson BA: Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival. Cancer Med. 8:928–938. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, et al: Low-Dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12:108–133. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Petragallo R, Bardach N, Ramirez E and Lamb JM: Barriers and facilitators to clinical implementation of radiotherapy treatment planning automation: A survey study of medical dosimetrists. J Appl Clin Med Phys. 23:e135682022. View Article : Google Scholar : PubMed/NCBI | |
|
Han-Oh S, Hill C, Kang-Hsin Wang K, Ding K, Wright JL, Alcorn S, Meyer J, Herman J and Narang A: Geometric reproducibility of fiducial markers and efficacy of a patient-specific margin design using deep inspiration breath hold for stereotactic body radiation therapy for pancreatic cancer. Adv Radiat Oncol. 6:1006552021. View Article : Google Scholar : PubMed/NCBI | |
|
Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, et al: Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 76 (3 Suppl):S70–S76. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Higgins K, Hu C, Ross H, Jabbour S, Kozono D, Owonikoko T, Dib E, Brownstein J, Kuzma C and Kotecha R: Concurrent chemoradiation±atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): results of NRG Oncology/Alliance LU005. Int J Radiat Oncol Biol Phys. 120:S22024. View Article : Google Scholar | |
|
Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, et al: Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS One. 11:e01571642016. View Article : Google Scholar : PubMed/NCBI | |
|
Gunderson AJ and Young KH: Exploring optimal sequencing of radiation and immunotherapy combinations. Adv Radiat Oncol. 3:494–505. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, Barsoumian HB, Younes AI, K Mahadevan LS, Soeung M, Aziz KE, Welsh JW and Krishnan S: Radiation therapy and immunotherapy: What is the optimal timing or sequencing? Immunotherapy. 10:299–316. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, et al: Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 Randomized clinical trial. JAMA Oncol. 5:1276–1282. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, et al: Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Erratum in: Lancet Respir Med. 9:e292021. | |
|
Postow MA, Sidlow R and Hellmann MD: Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 4:1721–1728. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, et al: Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 33:1217–1238. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, et al: Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:387–405. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al: Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 381:1535–1546. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, Hermes B, Cay Senler F, Csoszi T, Fulop A, et al: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A and Galle PR: Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 72:320–341. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jácome AA, Castro ACG, Vasconcelos JPS, Silva MHCR, Lessa MAO, Moraes ED, Andrade AC, Lima FMT, Farias JPF, Gil RA, et al: Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A meta-analysis. JAMA Netw Open. 4:e21361282021. View Article : Google Scholar : PubMed/NCBI | |
|
Li G, Zhao Y, Li K, Yang S, Xiang C, Song J, Yang Y, Li G and Dong J: Effectiveness and safety of the PD-1 inhibitor lenvatinib plus radiotherapy in patients with HCC with main PVTT: Real-world data from a tertiary centre. J Hepatocell Carcinoma. 10:2037–2048. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Y, Zhang Y, Zhang M, Zhao K, Feng L, Guan J, Dong R, Liu J, Tian D, Liu M, et al: Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect. Crit Rev Oncol Hematol. 189:1040702023. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Xiong L, Li M, Jiang P, Wang J and Li C: Advances in radiotherapy and immunity in hepatocellular carcinoma. J Transl Med. 21:5262023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen S, Xu B, Wu Z, Wang P, Yu W, Liu Z, Huang X, Wu Y, Li T and Guo W: Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: A multicenter retrospective study. BMC Cancer. 21:11262021. View Article : Google Scholar : PubMed/NCBI | |
|
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, et al: Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 6:17–29. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lewandowski RJ and Salem R: Radioembolisation with personalised dosimetry: Improving outcomes for patients with advanced hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 6:2–3. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu R, Wang X, Sun F, Zhu L and Guo W: Exploring the role of DNA methylation located in cuproptosis-related genes: Implications for prognosis and immune landscape in hepatocellular carcinoma. Front Biosci (Landmark Ed). 29:1232024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu J, Tang B, Lv X, Meng M, Weng Q, Zhang N, Li J, Fan K, Zheng L, Fang S, et al: Identifying apoptosis-related transcriptomic aberrations and revealing clinical relevance as diagnostic and prognostic biomarker in hepatocellular carcinoma. Front Oncol. 10:5191802021. View Article : Google Scholar : PubMed/NCBI | |
|
Nebhan CA and Johnson DB: Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. Expert Rev Anticancer Ther. 20:137–145. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu H, Liang XL, Liu XG and Chen NP: The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma. J Gastrointest Oncol. 12:1132–1140. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Parikh ND, Singal AG, Hutton DW and Tapper EB: Cost-effectiveness of hepatocellular carcinoma surveillance: An assessment of benefits and harms. Am J Gastroenterol. 115:1642–1649. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lani L, Stefanini B and Trevisani F: Surveillance for hepatocellular carcinoma in patients with successfully treated viral disease of the liver: A systematic review. Liver Cancer. 13:376–388. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Zafar SY, Alexander SC, Weinfurt KP, Schulman KA and Abernethy AP: Decision making and quality of life in the treatment of cancer: A review. Support Care Cancer. 17:117–127. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hamann J, Kissling W and Mendel R: Does it matter whether physicians' recommendations are given early or late in the decision-making process? An experimental study among patients with schizophrenia. BMJ Open. 6:e0112822016. View Article : Google Scholar : PubMed/NCBI | |
|
Nahm WJ, Bhatt A and Wu J: Role of radiotherapy and its contribution to immunotherapy in hepatocellular carcinoma. Chin Clin Oncol. 12:412023. View Article : Google Scholar : PubMed/NCBI |
